Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics has completed its entitlement offer, raising approximately $1 million through the issuance of new shares and options, though a shortfall of $2.2 million remains. The funds will support the company’s ongoing cell therapy programs, with trading of the new shares and options set to commence on 1 May 2025. The entitlement offer reflects continued shareholder support and positions Chimeric to further its innovative cancer treatment initiatives.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical-stage cell therapy company based in Australia, specializing in innovative treatments for cancer. The company focuses on the discovery, development, and commercialization of pioneering cell therapies, including autologous CAR-T and allogeneic NK cell therapies. Chimeric’s portfolio spans multiple oncology disease areas with four clinical stage programs, including CHM CDH17, CHM CLTX, and CHM CORE-NK therapies.
Technical Sentiment Signal: Buy
Current Market Cap: A$10.21M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue